Possible fetal outcome of insulin aspart

Basit Öğe Kaydı
dc.contributor.authorKanat, M.
dc.contributor.authorTahtacı, M.
dc.date.accessioned2021-06-23T19:25:47Z
dc.date.available2021-06-23T19:25:47Z
dc.date.issued2008
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractThe issue of whether insulin aspart and other analogues cross the human placenta is debated. We report a 31-yrold Type 2 diabetic multiparous woman who used insulin aspart at conception and during the first 6 weeks of pregnancy and had a baby with multiple congenital anomalies. She had excellent glucose control [glycated hemoglobulin (HbA1c) <5.6] with oral anti-diabetic agents when she came to our clinic and was considering becoming pregnant. Since she did not accept multiple injections, split dose insulin treatment was initiated [30% regular, 70% human isophane (NPH) insulin]. The patient’s blood glucose was regulated quite well during this treatment. However, the treatment was switched to analogue insulin at the same dosage (70% insulin aspart protamine suspension and 30% insulin aspart injection, Novo Nordisk formulation) by another doctor. At the next visit, she was 6-week pregnant; the analogue insulin was stopped and multiple injections were initiated (as mealtime regular and bedtime NPH) and this therapy was maintained until birth. No other drugs were used throughout the pregnancy. There was no consanguinity between parents. In the rest of the pregnancy, an optimal glucose regulation was provided (maximum fasting glucose <88 mg/dl, maximum post-prandial glucose <138 mg/dl, maximum HbA1c<6.1). She had a cesarean section at 29th gestational week and delivered a newborn with multiple congenital malformations including ambiguous genitalia due to 5-α reductase enzyme deficiency, anomalous course of left coronary artery, hemi-vertebra and horseshoe kidney. Theoretically, there could be at least 3 reasons explaining the fetal malformations in this baby: pre-gestational diabetes, maternal age, and insulin aspart that was used during the first 6 weeks of the pregnancy.en_US
dc.identifier.doi10.1007/BF03349265
dc.identifier.endpage841en_US
dc.identifier.issn1720-8386
dc.identifier.issue9en_US
dc.identifier.pmid18997497en_US
dc.identifier.scopus2-s2.0-57349128974en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage841en_US
dc.identifier.urihttps://doi.org/10.1007/BF03349265
dc.identifier.urihttps://hdl.handle.net/20.500.12491/6232
dc.identifier.volume31en_US
dc.identifier.wosWOS:000261148400015en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKanat, M.
dc.institutionauthorTahtacı, M.
dc.language.isoenen_US
dc.publisherItalian Society of Endocrinology (SIE)en_US
dc.relation.ispartofJournal Of Endocrinological Investigationen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInsulin Asparten_US
dc.titlePossible fetal outcome of insulin asparten_US
dc.typeLetteren_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
m.-kanat.pdf
Boyut:
74.06 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu